Moraxella catarrhalis has been recognized as an important cause of upper respiratory tract and middle ear infections in children, as well as chronic obstructive pulmonary disease and chronic bronchitis in adults. We aim to study the clonal structure, antimicrobial resistance, and serotypes of M. catarrhalis strains recovered from patients of different ages. Nasopharyngeal swabs, middle ear fluid, and sputum samples were collected. In vitro susceptibility testing was performed according to EUCAST criteria. The monoclonal Ab hybridoma technique was used for serotyping. All strains were subjected to MLST. The studied population demonstrated susceptibility to all tested antimicrobials M. catarrhalis strains, with the majority being serotype A (90.4%), followed by B (6.8%), and C (2.7%). We observed a predominant clonal complex CC224 (21.9%) along with other clusters including CC141 (8.2%), CC184 (8.2%), CC449 (6.8%), CC390 (5.5%), and CC67 (2.7%). Two primary founders, namely, ST224 and ST141, were identified. The analyzed genetic lineages displayed diversity but revealed the predominance of two main clusters, CC224 and CC141, encompassing multidrug-resistant sequence types distributed in other regions. These data underscore the need for ongoing epidemiological monitoring of successfully circulating clones and the implementation of adequate antibiotic policies to limit or delay the spread of multidrug-resistant strains in our region.

Delafloxacin is one of the newest fluoroquinolones with a unique structure, determining better pharmacokinetic and pharmacodynamic properties, a better safety profile, and a broader spectrum of activity compared to older quinolones. We aimed to examine the susceptibility rates of delafloxacin, the genetic mechanisms contributing to resistance, and the serotype distribution in both invasive and non-invasive Streptococcus agalactiae strains. A total of 301 streptococcal strains were tested for minimal inhibitory concentration (MIC) to delafloxacin. All delafloxacin-resistant strains were subjected to serotyping, PCRs for quinolone-resistant genes, and sequence analysis for missense and silent mutations. Among the tested isolates, we found a 5.6% non-susceptibility rate to delafloxacin. The MICs ranged between 0.09 and 0.38 µg/mL, with a breakpoint for nonsusceptibility set as >0.03 µg/L, according to EUCAST criteria. All resistant isolates harboured missense mutations that led to amino acid substitutions in both GyrA (S81L) and ParC (S79F). Two common serotypes were determined among the resistant isolates: V (47.1%) and III (41.2%). Two strains were non-typable (11.7%). A statistical significance in the distribution of serotypes between delafloxacin-resistant and delafloxacin-susceptible strains was found. These findings highlight a concerning pattern of drug resistance developing prior to the introduction of a new medication, attributed to the extensive use of current antibiotics.